182291-43-6Relevant articles and documents
Orally active thrombin inhibitors. Part 1: Optimization of the P1-moiety
Mack, Helmut,Baucke, Dorit,Hornberger, Wilfried,Lange, Udo E.W.,Seitz, Werner,Hoeffken, H. Wolfgang
, p. 2641 - 2647 (2008/12/21)
The synthesis and SAR of novel nanomolar thrombin inhibitors with the common backbone HOOC-CH2-d-cyclohexylalanyl-3,4-dehydroprolyl-NH-CH 2-aryl-C(double bond, long NH)NH2 are described together with their ecarin clotting
Technical scale synthesis of a new and highly potent thrombin inhibitor
Bernard, Harald,Buelow, Gerd,Lange, Udo E. W.,Mack, Helmut,Pfeiffer, Thomas,Schaefer, Bernd,Seitz, Werner,Zierke, Thomas
, p. 2367 - 2375 (2007/10/03)
In this account, we describe the development of an efficient and convergent process for the peptidomimetic thrombin inhibitor 1 on production plant scale. Starting from nicotinonitrile (13), (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxy-2- pyrrolidinecarboxylic acid (5) and (2R)-2-amino-3-cyclohexylpropanoic acid (29) compound 1 was obtained in 16 chemical steps. New methods had been developed for the preparation of the key intermediate dehydroproline 22 and the transformation of nitriles into amidines. The thrombin inhibitor 1 was isolated by special techniques (nanofiltration and spray drying). Almost all salts of 1 are amorphous, however, a crystalline complex was obtained with 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (Saccharin).